New Oral Formulations of Amphotericin B Show Less Toxicity Against Candida
Author Information
Author(s): Leon Carlos G, Lee Jinkyung, Bartlett Karen, Gershkovich Pavel, Wasan Ellen K, Zhao Jinying, Clement John G, Wasan Kishor M
Primary Institution: The University of British Columbia
Hypothesis
The study aims to determine the cytotoxicity of two novel Amphotericin B formulations against Candida albicans and human cell lines.
Conclusion
The novel formulations iCo-009 and iCo-010 showed no cytotoxicity to kidney cells and higher efficacy against Candida albicans compared to existing formulations.
Supporting Evidence
- None of the AmpB formulations tested showed cytotoxicity against 293T cells.
- Cytotoxicity in THP1 cells was observed for Fungizone™ and Ambisome™, but not with the novel formulations.
- iCo-010 had higher efficacy compared to other formulations in the Candida albicans model.
Takeaway
The new versions of a medicine called Amphotericin B are safer and work better against a type of fungus than older versions.
Methodology
Cell cytotoxicity was evaluated using MTS and LDH assays after a 48-hour drug incubation.
Limitations
Limited correlation between in vitro susceptibility and patient response.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website